Literature DB >> 10360582

A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation.

G Tisone1, M Angelico, G Palmieri, F Pisani, A Anselmo, L Baiocchi, S Negrini, G Orlando, G Vennarecci, C U Casciani.   

Abstract

BACKGROUND: Corticosteroids are commonly used in the immunosuppression therapy after liver transplantation, yet are associated with considerable side effects. Retrospective studies have shown that corticosteroids can be safely withdrawn from months to years after transplant. We prospectively investigated the effects of early immunosuppression without the use of corticosteroids on graft outcome and transplant complications.
METHODS: Forty-five patients undergoing liver transplantation were randomized to receive immunosuppression composed of cyclosporine microemulsion and azathioprine with (n=22) or without prednisone (n=23), in conventional doses. In those patients who received prednisone, this was withdrawn within 3 months after transplant. The median follow-up of survivors was 14 months (range: 6-24). The study end points were to determine graft survival and function, infectious complications, including hepatitis C virus (HCV)-RNA levels in HCV-infected recipients, acute rejection, kidney function, and metabolic complications.
RESULTS: Eleven deaths occurred, 6 of which were in the prednisone group. Two-year survival did not differ between patients treated with or without prednisone (70.2% vs. 78.3%, P=0.83), nor did the causes of death. No differences were observed with regard to graft function, renal function, and infectious complications. In the subset of patients who received transplants for HCV-related cirrhosis, the dynamics of virus replication HCV-RNA was faster among those treated with prednisone. The incidence and severity of acute rejection was similar in the two groups. More than 80% of acute rejections in both groups were classified as mild or moderate and underwent spontaneous resolution. Only two patients in each group had severe acute rejection requiring additional treatment with high-dose steroids. Patients receiving prednisone tended to have greater biochemical signs of cholestasis, higher serum cholesterol and glucose levels, and more frequent insulin requirement than those treated without corticosteroids.
CONCLUSIONS: Liver transplantation can be performed safely without using corticosteroids in the early postoperative course, and there is no need for routine aggressive steroid treatment of established acute rejections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360582     DOI: 10.1097/00007890-199905270-00003

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

Review 1.  Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review.

Authors:  George Sgourakis; Georgia Dedemadi
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial.

Authors:  Khurram Bari; Shimul A Shah; Tiffany E Kaiser; Robert M Cohen; Nadeem Anwar; David Kleesattel; Kenneth E Sherman
Journal:  Liver Transpl       Date:  2020-08-19       Impact factor: 5.799

Review 3.  Corticosteroid-free strategies in liver transplantation.

Authors:  John G O'Grady
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Higher tacrolimus blood concentration is related to hyperlipidemia in living donor liver transplantation recipients.

Authors:  Hong-Yu Li; Bo Li; Yong-Gang Wei; Lv-Nan Yan; Tian-Fu Wen; Ji-Chun Zhao; Ming-Qing Xu; Wen-Tao Wang; Yu-Kui Ma; Jia-Yin Yang
Journal:  Dig Dis Sci       Date:  2011-07-09       Impact factor: 3.199

Review 5.  Options for induction immunosuppression in liver transplant recipients.

Authors:  Michael A J Moser
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

Authors:  Shawn J Pelletier; Satish N Nadig; David D Lee; John B Ammori; Michael J Englesbe; Randall S Sung; John C Magee; Robert J Fontana; Jeffrey D Punch
Journal:  HPB (Oxford)       Date:  2012-09-28       Impact factor: 3.647

7.  Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis.

Authors:  Perdita Wietzke-Braun; Felix Braun; Burckhart Sattler; Giuliano Ramadori; Burckhardt Ringe
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 8.  Single-agent immunosuppression after liver transplantation: what is possible?

Authors:  Maria L Raimondo; Andrew K Burroughs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Current concepts and perspectives of immunosuppression in organ transplantation.

Authors:  Marcus N Scherer; Bernhard Banas; Kiriaki Mantouvalou; Andreas Schnitzbauer; Aiman Obed; Bernhard K Krämer; Hans J Schlitt
Journal:  Langenbecks Arch Surg       Date:  2007-04-21       Impact factor: 3.445

Review 10.  Management of immunosuppressant agents following liver transplantation: Less is more.

Authors:  Mustafa S Ascha; Mona L Ascha; Ibrahim A Hanouneh
Journal:  World J Hepatol       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.